ArticleFrontiers in public health2026
Higher plasma omega-6 fatty acids are associated with lower dementia risk: evidence from NMR metabolomics and Alzheimer's disease polygenic risk in the UK Biobank.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Circulating polyunsaturated fatty acids (PUFAs) have been implicated in neurodegenerative processes, yet epidemiological evidence remains inconsistent. Genetic susceptibility to Alzheimer's disease (AD), commonly indexed by a polygenic risk score (PRS), is a major determinant of dementia risk. However, few large-scale prospective studies have jointly examined plasma fatty acid profiles and genetic liability to AD in relation to incident dementia. Objectives: To investigate the independent and combined associations of plasma omega-3 PUFAs, omega-6 PUFAs, and the omega-6/omega-3 ratio with incident dementia, and to determine whether these associations vary according to AD-PRS. Methods: We analyzed data from 81,827 UK Biobank participants with baseline nuclear magnetic resonance (NMR) metabolomics and genetic information. Plasma fatty acids were quantified using standardized NMR spectroscopy, and genetic risk for AD was assessed using the Enhanced AD-PRS. Incident dementia was identified through linked hospital admission and death registry records. Multivariable-adjusted hazard ratios (HRs) were estimated using Cox proportional hazards models. Dose-response relationships and both additive and multiplicative interactions with AD-PRS were evaluated, alongside subgroup and sensitivity analyses. Results: Over a median follow-up of 12.1 years, 1,335 participants developed dementia. Higher plasma omega-6 concentrations were consistently associated with a lower risk of dementia, corresponding to an approximately 15% risk reduction per 1 mmol/L increase (HR 0.85, 95% CI 0.79-0.93, Conclusions: Higher plasma omega-6 PUFA levels were independently associated with a clinically meaningful reduction in dementia risk, whereas omega-3 PUFAs and the omega-6/omega-3 ratio were not. Although elevated omega-6 modestly reduced absolute risk among individuals with high genetic susceptibility to AD, no meaningful gene-nutrient interaction was detected. Further mechanistic and interventional studies are warranted to elucidate underlying pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.